Ongoing pregnancy qualifies best as the primary outcome measure of choice in trials in reproductive medicine An opinion paper

Arguments for the use of ongoing pregnancy rate as primary outcome of comparative effectiveness research in reproductive medicine are discussed.

Like Comment

Authors

Miriam Braakhekke, M.D., Esme I. Kamphuis, M.D., Eline A. Dancet, Ph.D., Femke Mol, M.D., Ph.D., Fulco van der Veen, M.D., Ph.D., Ben W. Mol, M.D., Ph.D.

Volume 101, Issue 5, Pages 1203–1204

Abstract

The most appropriate primary outcome measure for reproductive medicine has been discussed frequently. In 2003 the European Society for Human Reproduction and Embryology recommended that the outcome measure of assisted reproductive technology (ART) and non-ART should be singleton live birth. Although live birth is indeed the aim of clinical practice, and there is no discussion that it should be reported in infertility trials, we hereby provide arguments that plead for using ongoing pregnancy as the primary outcome in such trials. We feel that ongoing pregnancy best serves the many purposes of a primary outcome and best reflects the effectiveness of a treatment.

Read the full text at: http://www.fertstert.org/article/S0015-0282(14)00302-1/fulltext


Go to the profile of Fertility and Sterility

Fertility and Sterility

Editorial Office, American Society for Reproductive Medicine

Fertility and Sterility® is an international journal for obstetricians, gynecologists, reproductive endocrinologists, urologists, basic scientists and others who treat and investigate problems of infertility and human reproductive disorders. The journal publishes juried original scientific articles in clinical and laboratory research relevant to reproductive endocrinology, urology, andrology, physiology, immunology, genetics, contraception, and menopause. Fertility and Sterility® encourages and supports meaningful basic and clinical research, and facilitates and promotes excellence in professional education, in the field of reproductive medicine.

No comments yet.